Mazdutide alternatives.
10 compounds compared to Mazdutide, ranked by published evidence tier and regulatory status, not by what's marketed hardest.
Mazdutide searches split by geography. Its development is furthest along in China, where it has moved through Phase 3 and been pursued for regulatory filing in obesity and overweight, so people inside that market are typically comparing it to other options on the same shelf. Everyone else is looking for an alternative because mazdutide is not approved by the FDA or EMA and any use outside an authorized trial is unapproved. In that case the comparison worth making is against the incretin drugs that are approved where you live, not against the other GLP-1 and glucagon dual agonists still working through their programs.
Mazdutide (IBI362, originally LY3305677) is an investigational once-weekly injectable dual agonist of the GLP-1 and glucagon receptors, based on a mammalian oxyntomodulin analog.
- 01SurvodutideB tierIn human trialsBI 456906
Acts through the glp-1 receptor agonism pathway, like Mazdutide. In human trials.
- 02RetatrutideB tierIn human trialstriple agonist
Acts through the glp-1 receptor agonism pathway, like Mazdutide. In human trials.
- 03SemaglutideS tierFDA-approvedOzempic · Wegovy
Acts through the glp-1 receptor agonism pathway, like Mazdutide. FDA-approved.
- 04LiraglutideS tierFDA-approvedVictoza · Saxenda
Acts through the glp-1 receptor agonism pathway, like Mazdutide. FDA-approved.
- 05TirzepatideS tierFDA-approvedMounjaro · Zepbound
Acts through the glp-1 receptor agonism pathway, like Mazdutide. FDA-approved.
- 06CagriSemaC tierIn human trialscagrilintide + semaglutide
Acts through the glp-1 receptor agonism pathway, like Mazdutide. In human trials.
- 07
- 08AOD-9604D tierResearch / preclinical
Same category: metabolic & glp-1. Research / preclinical.
- 09HGH Fragment 176-191F tierResearch / preclinicalhGH frag 176-191 · GH lipolytic fragment
Same category: metabolic & glp-1. Research / preclinical.
- 10
An “alternative” here means a compound that shares Mazdutide's mechanism pathway or sits in the same category, not a marketing substitute. Each is ordered by PepCue's evidence tier (a weighted 0–100 score across human data, safety, replication and regulatory clarity), then by whether it's actually approved. This is a research reference, not medical or purchasing advice: an alternative sitting higher on evidence does not mean it's right, safe, or legal for any given use. Reviewed June 1, 2026.
PepCue keeps every compound, dose and lab in one private, provider-ready timeline, whichever one you land on.